STSarah E. Taylor

Sarah E. Taylor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sarah E. Taylor has a total of 257 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CT ‐Derived Body Composition Enhances Risk Prediction for Early Progression and Platinum Resistance in High‐Grade Serous Ovarian Cancer

    by Jatin Singh, Xin Meng, Grant Kokenberger, Jianbing Zhu, Lauren Borho, Esther Elishaev, Sarah Taylor, Francesmary Modugno, Jiantao Pu

    Background: Patients with high‐grade serous ovarian cancer (HGSOC) who develop resistance to platinum‐based chemotherapy experience significantly poorer outcomes and shorter progression‐free survival (PFS). This study evaluates whether pretreatment CT‐based abdominal body composition is associated with platinum resistance and PFS, and whether its incorporation alongside clinical variables improves prognostic model performance. Methods: This retrospective study included 321 patients with HGSOC (mean age 65 ± 10 years; 28.0% platinum‐resistant) treated with platinum‐based chemotherapy between 2011 and 2023. Deep learning algorithms quantified abdominal body composition features from pretreatment CT scans, including skeletal muscle, bone, subcutaneous (SAT), visceral (VAT), and intramuscular (IMAT) adipose tissues. Platinum resistance, defined as disease progression during therapy or within 6 months of the final infusion, was the primary outcome. PFS was analyzed as a secondary outcome using Cox proportional hazards modeling. Analyses were stratified by chemotherapy sequence (neoadjuvant vs. adjuvant). Survival models incorporating clinical and CT‐derived features were evaluated using 10‐fold cross‐validated time‐dependent AUC over a 5‐year follow‐up window to predict PFS. External validation was partially performed in an independent cohort of 58 patients with HGSOC. Results: Increased SAT and IMAT and decreased skeletal muscle density were independently associated with platinum resistance, with high SAT remaining significant in both the internal and external cohorts ( p < 0.05). High adiposity and low muscle density were similarly associated with shorter PFS. Survival models combining clinical and CT‐derived features consistently outperformed clinical‐only models across all evaluated model classes. The Elastic Net Cox regression model incorporating both feature sets achieved the highest AUC of 0.704 (95% CI: 0.660–0.748). Conclusions: Pretreatment CT‐derived abdominal body composition is independently associated with platinum resistance and PFS in HGSOC, and its incorporation into predictive clinical models improves discrimination. Body composition assessment may help identify patients at increased risk of platinum resistance and early disease progression.

  • What is the optimal fractionation for image-based high-dose-rate brachytherapy boost in medically inoperable endometrial cancer: 4 versus 5 fractions?

    by Abigail Groszkiewicz, Jamie L. Lesnock, Paniti Sukumvanich, Michelle Boisen, Madeleine Courtney-Brooks, Jessica Berger, Sarah Taylor, Alexander Olawaiye, Alison Garrett, Shannon Rush, et al.

  • Open Access

    Prognostic Value of Lymphoid Infiltration and Aggregation in Cervical Cancer

    by Grace Gorecki, Macy Hale, Sarah Taylor, Geyon Garcia, Ian P. MacFawn, T. Rinda Soong, Tullia C. Bruno, Lan Coffman

    Background/objectives: Understanding the immune landscape in cervical cancer is critical to the development of improved therapeutics. This study investigated the immune microenvironment in early-stage cervical cancer with a focus on B and T cell immune aggregates, i.e., lymphoid aggregates (LAs) and tertiary lymphoid structures (TLSs). Methods: Using multispectral imaging, we interrogated a cohort of patients with clinical stage I squamous or adenocarcinoma of the cervix with a focus on T and B cell spatial location and organization. Despite early-stage disease, recurrence was common at 37%, highlighting the need to identify patients at high risk for recurrence. Results: We demonstrated that high CD8+ T cell infiltration correlated significantly with improved overall survival (OS), particularly in patients with adenocarcinoma histology. CD8+ T cells colocalized with B cells, suggesting the formation of a more sophisticated cellular neighborhood, i.e., TLS, which has prognostic benefit in other solid tumors. CXCL13, a chemokine associated with TLS formation, correlated with improved recurrence-free survival. The combination of high CXCL13 and lymphoid structures correlated with improved OS. However, most immune structures in cervical cancer were lymphoid aggregates (LAs) that lack features of more developed TLS, such as high endothelial venules (HEVs) and germinal centers (GCs), highlighting a lack of full immune activation in this microenvironment. Validation in The Cancer Genome Atlas (TCGA) cohort illustrated similar trends in survival. Conclusions: Collectively, this work demonstrates the prognostic significance of immune infiltration and eventual TLS induction in early cervical cancer and presents potential future therapeutic targets.


  • Association of health care policy and trends in cancer screening during the COVID-19 pandemic

    by Daniel L. Pelzman, Danielle Sharbaugh, Jonathan G. Yabes, Jonathan Lin, Maria Pere, Ravy Vajravelu, David Wilson, Margarita Zuley, Sarah Taylor, Benjamin J. Davies, et al.

  • Twice daily template-based interstitial brachytherapy for gynecologic cancers: What is the optimal dose?

    by Ria Mulherkar, David Grimm, Paniti Sukumvanich, Madeleine Courtney-Brooks, Michelle Boisen, Jessica Berger, Sarah Taylor, Jamie Lesnock, Shannon Rush, Allison Garrett, et al.


  • Open Access

    Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma

    by Yasushi Iida, Michael Churchman, Robert L Hollis, Sarah Taylor, Clare Bartos, Ian Croy, William Gentleman, Tzyvia Rye, Rachel Nirsimloo, C. Simon Herrington, et al.

    Objective: Clear cell ovarian carcinoma (CCOC) is generally associated with a favourable prognosis, but up to 30% of low-stage cases relapse within five years. The benefit of adjuvant chemotherapy for low-stage CCOC (FIGO stage IA-IC1) remains uncertain. This study aimed to identify molecular and immune markers associated with relapse in a well-characterized CCOC cohort. Methods: Using the Edinburgh Ovarian Cancer Database, we identified 85 CCOC cases. Targeted DNA sequencing assessed genomic alterations and tumour immune infiltration was evaluated using CD3 and CD8 immunohistochemistry on tissue microarrays. Tumours were stratified by stage (IA-IC1, IC2-II, III-IV), and both univariate and multivariate analysis applied for progression-free survival (PFS) included stage, age, genomic features, and immune markers. Results: Common genomic alterations included ARID1A (49%) and PIK3CA (42%) mutations, PIK3-AKT pathway perturbations (60%), and mismatch repair-related mutational signatures (25.9%). Genomic and molecular features were not significantly associated with tumour stage; however, low-stage tumours (IA-IC1) were enriched in CD3+ (40% cases) and CD8+ (29% cases) tumour-infiltrating lymphocytes (TILs) compared to higher-stage tumours (IC2-II: 13%/7%; III-IV: 9%/0% cases). In univariate analysis, low CD3+ TIL levels were significantly associated with reduced progression-free survival (HR = 4.4, P = 0.042, 95% CI 1.1-18). ARID1A wild-type status was linked to poorer PFS but only in low-stage tumours HR = 7.2, P = 0.088; 95% CI 0.74-72). Notably, the combination of ARID1A wild-type status and CD3+ depletion identified a high-risk subgroup among low-stage CCOC cases (HR = 11.7, P = 0.050; 95% CI 1-138), highlighting potential as a composite risk marker set. Conclusions: Combined ARID1A mutation and low CD3+ve TIL levels are suggestive of higher recurrence risk in low-stage CCOC patients. These findings support further investigation of targeted therapies or immune checkpoint inhibitors in larger CCOC cohorts. Highlights: We report a well-characterized CCOC cohort with rich clinical, genomic and molecular data. Common mutations included ARID1A (49%) and PIK3CA (42%), with MSI in 9%, showing no significant enrichment across tumour stages. Low-stage CCOC has higher levels of CD3+ & CD8+ tumour infiltrating leukocytes than in advanced-stage disease. ARID1A wild-type tumours with CD3+ TIL depletion represent a high-risk subgroup of low-stage CCOC. Findings support further study and highlight potential markers for recurrence risk.

  • Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)

    by Sarah E. Taylor, Sarah Behr, Kristine L. Cooper, Haider Mahdi, Denise Fabian, Holly Gallion, Frederick Ueland, John Vargo, Brian Orr, Eugenia Girda, et al.

    Background The addition of IV triapine to chemoradiation appeared active in phase I and II studies but drug delivery is cumbersome. We examined PO triapine with cisplatin chemoradiation. Methods We implemented a 3 + 3 design for PO triapine dose escalation with expansion, starting at 100 mg, five days a week for five weeks while receiving radiation with weekly IV cisplatin for locally advanced cervical or vaginal cancer. Maximum tolerated dose (MTD), dose limiting toxicity (DLT), adverse events, pharmacokinetics (PK), pharmacodynamics (PD), and metabolic complete response (mCR) were assessed. Results 19/21 patients were DLT evaluable. DLTs included grade 4 neutropenia (n = 2), leukopenia (n = 2), lymphopenia (n = 2), and hypokalemia (n = 1). Grade 3 toxicities at least possibly related were as expected for cisplatin chemoradiation: lymphopenia (n = 12), anemia (n = 10), neutropenia (n = 4), leukopenia (n = 8), decreased platelets (n = 2), hypertension (n = 1), and hyponatremia (n = 1). MTD and RP2D were established at 100 mg. 8/13 evaluable patients had a mCR. Triapine had a bioavailability of 59%. Methemoglobin levels correlated with triapine exposure. Smoking almost doubled CYP1A2 mediated triapine clearance. Conclusions Oral triapine is safe when given with cisplatin chemoradiation, convenient, bioavailable. Exposure is negatively impacted by smoking, and methemoglobin is a biomarker of exposure. Clinical trial registration NCT02595879.


  • Open Access

    Figure 3 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

    by Flurina A.M. Saner, Kazuaki Takahashi, Timothy Budden, Ahwan Pandey, Dinuka Ariyaratne, Tibor A. Zwimpfer, Nicola S. Meagher, Sian Fereday, Laura Twomey, Kathleen I. Pishas, et al.

    Genomic landscape of high-grade serous ovarian tumors with co-occurring BRCA and RB1 alterations. A, Pathogenic germline and somatic alterations in HR and DNA repair genes detected by whole-genome sequencing and DNA methylation analysis of 126 primary HGSC samples (27) are shown, as well as alterations in immune genes and CCNE1. Samples are grouped by HR and RB1 status. Bars at the top indicate the number of alterations in each listed gene per patient. Patients are annotated with survival group (LTS, long-term survivor, OS > 10 years; MTS, mid-term survivor, OS 2–10 years; STS, short-term survivor, OS < 2 years), tumor CHORD (41) scores, and the proportion of structural variant (SV) type (DEL, deletion; DUP, duplication; INV, inversion; ITX, intra-chromosomal translocation). B, Kaplan–Meier estimates of progression-free survival (left) and overall survival (right) of patients according to HR status (BRCA1-type HRD; BRCA2-type HRD; or HRP tumors) and RB1 status (altered vs. wild-type).

  • Open Access

    Supplementary Table S12 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

    by Flurina A.M. Saner, Kazuaki Takahashi, Timothy Budden, Ahwan Pandey, Dinuka Ariyaratne, Tibor A. Zwimpfer, Nicola S. Meagher, Sian Fereday, Laura Twomey, Kathleen I. Pishas, et al.

    Supplementary Table S12. Clinical characteristics of patients with HGSC.

  • Open Access

    Supplementary Table S17 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

    by Flurina A.M. Saner, Kazuaki Takahashi, Timothy Budden, Ahwan Pandey, Dinuka Ariyaratne, Tibor A. Zwimpfer, Nicola S. Meagher, Sian Fereday, Laura Twomey, Kathleen I. Pishas, et al.

    Supplementary Table S17. Half maximum inhibitory concentrations (IC50) for cisplatin (72 hours), paclitaxel (72 hours), or olaparib (120 hours) in HGSC cell lines with innate RB1 and/or BRCA1 alterations.